NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study
nucana公司发布癌症治疗结果，看到在1b/2期研究中部分反应。
NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid
NuCana plc（纳斯达克股票代码：NCNA）宣布，正在进行的 1b/2 期模块化研究（Nutide: 303）的初步数据显示，该研究研究 NUC-3373 与 PD-1 抑制剂 pembrolizumab 联合用于晚期固体患者
NuCana plc (NASDAQ:NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lung cancer (Module 2) have been published in MedRxiv, the preprint server for Health Sciences.
NuCana plc（纳斯达克股票代码：NCNA）宣布，正在进行的1b/2期模块化研究（Nutide: 303）的初始数据已在健康科学预印本服务器medrXiv上公布，该研究旨在研究 NUC-3373 与PD-1抑制剂pembrolizumab联合治疗晚期实体瘤患者（模块1），以及与多西他赛联合治疗肺癌患者（模块2）。
Module 1 included 12 patients with a variety of solid tumors who had exhausted all other treatment options. The majority...
模块1包括12名患有各种实体瘤的患者...
登录免费看全文
登录/注册
资讯热榜
更新时间